
Opinion|Videos|May 21, 2024
CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC
5. Frank Scimeca, PharmD, MBA, BCOP, leads a discussion on sequencing CDK4/6 inhibitors, comparing their side effect profiles, toxicity benefits, and progression-free survival (PFS) advantages. He emphasizes the need for additional biomarkers and clearer guidance from the NCCN to aid in selecting the most appropriate drug for each patient.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
2
Adrabetadex Becomes First Therapy Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease Type C
3
When Medicine Changes Faster Than Health Care: Preparing for a New Era
4
The DOL PBM Disclosure Rule Puts Pharmacy Clawbacks on the Table—Pharmacy Teams Should Be Ready
5



